OXFORD BIOMEDICA
Oxford BioMedica is a pioneer of gene and cell therapy, with a leading industry position in lentiviral vector and cell therapy research, development and manufacture. Gene therapy is the treatment of disease by delivering therapeutic DNA into a patient’s cells. This can be either in vivo or ex vivo, the latter encompassing the field of cell therapy whereby genetically modified cells are put back into the body. Their pipeline of seven gene and cell therapy therapy products addresses diseases for... which there is currently no treatment or that are inadequately treated today, including ocular and central nervous system disorders. Their product candidates have the potential to transform treatment landscapes. Their strategy is to develop their product candidates to their next value inflection points whilst continuing to build OXB Solutions into a valuable revenue-generating manufacturing and development services business.
OXFORD BIOMEDICA
Industry:
Biotechnology Genetics Therapeutics
Founded:
1995-01-01
Address:
Oxford, Oxfordshire, United Kingdom
Country:
United Kingdom
Website Url:
http://www.oxb.com
Total Employee:
51+
Status:
Active
Contact:
+4401865783000
Total Funding:
62.3 M GBP
Technology used in webpage:
SPF Domain Not Resolving Google Maps Microsoft Azure DNS GoDaddy DNS Google Maps API Mimecast
Similar Organizations
4BIO Capital
4BIO Capital is a specialist fund focused on investing in and building early stage advanced therapy companies
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Amsterdam Scientific Instruments
Amsterdam Scientific Instruments specializes in the fields of neutron detection, electron imaging, and X-ray detector technology.
Arctos Medical
Arctos Medical is a developed gene therapy that does not correct rare genetic eye diseases but much more common cases of blindness.
arGEN-X
arGEN-X offers a platform for antibody lead choice that supports the discovery of human antibody therapeutics.
Batavia Biosciences
Batavia Biosciences focuses on accelerating the transition of biopharmaceutical product
BioCryst Pharmaceuticals
BioCryst has over 80 employees spread across their two locations in Birmingham, Alabama and Durham, North Carolina.
Celyad
Celyad is a provider of cell therapy treatments with an initial focus on cardiology and oncology.
Chameleon Biosciences
Chameleon Biosciences is transforming gene therapy with a re-dosable, AAV based gene therapy.
DNAdigest
DNAdigest is a scientific social enterprise that enables the secure sharing and query of genomics data for research.
EG 427
EG 427 is a French biotechnology company that pioneers a new approach in gene therapy called pinpoint gene therapy.
Enara Bio
Ervaxx is illuminating the immune interface to develop new cancer therapies.
Evaxion Biotech
Evaxion Biotech is devoted to the discovery and development of vaccines against cancer and infectious diseases.
Fulcrum Therapeutics
Fulcrum Therapeutics is a biotechnology company that develops new medicines to treat patients with rare genetic diseases.
Genetic Analysis
Genetic Analysis has the goal of being a leader within the field of molecular diagnostics of diseases related to gut imbalances.
Hookipa Pharma
Hookipa is a clinical stage biotech company developing best-in-class active immunization therapies for infectious diseases and oncology.
Coave Therapeutics
Horama develops gene therapies for rare inherited ocular and CNS (central nervous system) diseases.
Horizon Discovery
Horizon is a gene editing company that designs & engineers genetically-modified cells, applying them to advance human health.
Hybrigenics
Hybrigenics offers a bioinformatics platforms to identify, validate, and inhibit protein interactions to develop therapeutics for cancer.
immatics biotechnologies
immatics is a biopharmaceutical company focused on the development of immunotherapeutic substances for cancer therapy.
Immunovia
Immunovia is the center for translational cancer research in Lund, Sweden.
Intima Biosciences
Intima Biosciences is a cell therapy business that focuses on solid tumor cancer cures.
Nouscom
Nouscom are a biotech company working to develop a series of new, potent immunotherapeutics capable of selectively killing tumor cells.
Oxford Nanopore Technologies
Oxford Nanopore Technologies develops nanopore-based electronic systems for analyzing single molecules, including DNA, RNA, and proteins.
Oxford Science Enterprises
Oxford Science Enterprises a university-partnered venture firm, investing in early-stage life science, AI & software, and deep tech.
Translate Bio
Translate Bio is a biotechnology company that specializes in biotechnology, RNA therapeutics, and rare diseases.
Reithera Srl
Reithera Srl is a company devoted to develop and produce biopharmaceutical products based on gene delivery technologies
Riboxx
Riboxx LIFE SCIENCES develops customized and tailor-made molecular tools for gene silencing in vitro and in vivo through RNA interference:
RoslinCT
RoslinCT is a UK Cell Therapy Contract Development and Manufacturing Organisation.
Sino-Biocan
Sino-Biocan focuses on the research and development of domestic tools in the field of cell and gene therapy.
T-knife
T-knife is a developer of T cell receptors intended for T cell therapy of cancer.
Xenothera
Xenothera is a xenotherapy platform with embedded technology that renovates immunological treatments.
Current Advisors List
Board_member
2022-01-01
Advisor
Board_member
2020-01-01
Current Employees Featured
Kyriacos Mitrophanous Chief Scientific Officer @ Oxford BioMedica
Chief Scientific Officer
Stuart Paynter Chief Financial Officer @ Oxford BioMedica
Chief Financial Officer
Jason Slingsby Chief Business Officer @ Oxford BioMedica
Chief Business Officer
James Miskin Chief Technical Officer @ Oxford BioMedica
Chief Technical Officer
2014-10-01
Lorenzo Tallarigo Chairman @ Oxford BioMedica
Chairman
Helen Stephenson-Ellis Chief People Officer @ Oxford BioMedica
Chief People Officer
Dmitry Zamoryakhin Chief Medical Officer @ Oxford BioMedica
Chief Medical Officer
Nick Page Chief Operations Officer @ Oxford BioMedica
Chief Operations Officer
David Davies Programme Director (interim) @ Oxford BioMedica
Programme Director (interim)
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2007-03-12 | Oxxon Therapeutics | Oxxon Therapeutics acquired by Oxford BioMedica | 16 M GBP |
Investors List
Serum Institute of India Pvt. Ltd.
Serum Institute of India Pvt. Ltd. investment in Post-IPO Equity - Oxford BioMedica
Innovate UK
Innovate UK investment in Grant - Oxford BioMedica
Official Site Inspections
http://www.oxb.com Semrush global rank: 496.53 K Semrush visits lastest month: 100.57 K
- Host name: 141.193.213.10
- IP address: 141.193.213.10
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Oxford BioMedica"
Oxford Biomedica - Wikipedia
The company was established in 1995 as a spin out from the University of Oxford. It was the subject of an initial public offering on the Alternative Investment Market in 1996. In 2018, OXBs gene therapy for Parkinson's disease became the subject of a commercialization deal with Axovant Sciences. In May 2019, the company announced an investment by Novo Holdings for a stake of 10.1% in …See details»
Let’s deliver life-changing therapies together - OXB
25+ years enabling the world’s most progressive and successful viral vector therapies. Full service offering, supported by robust quality systems.See details»
About OXB | PharmiWeb.jobs
Mar 12, 2025 OXB is a global quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its …See details»
OXB, OXB:LSE profile - FT.com - Financial Times
3 days ago Oxford Biomedica PLC is a contract development and manufacturing organization (CDMO) in cell and gene therapy. It provides viral vector development and manufacturing …See details»
Dr Frank Mathias to join Oxford Biomedica as new CEO on 27 …
Feb 20, 2023 Dr Mathias brings a wealth of experience in innovation, contract development and manufacturing to Oxford Biomedica Stuart Henderson to take on newly created position of …See details»
Oxford Biomedica rebrands as OXB reinforcing transformation into ...
Sep 18, 2024 OXB (LSE: OXB) is a quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its …See details»
Oxford Biomedica plc (OXB.L) - Yahoo Finance
See the company profile for Oxford Biomedica plc (OXB.L) including business summary, industry/sector information, number of employees, business summary, corporate governance, …See details»
Integrity and Ethics at OXB
The Board of Directors has approved a Modern Slavery Statement 2023 in compliance with section 54 of the UK Modern Slavery Act, which can be downloaded from the Group’s website …See details»
More documents for Oxford Biomedica (Group) - Life-Sciences …
Oxford Biomedica (LSE:OXB) is a leading, fully integrated, gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford Biomedica and its …See details»
Quality - careers.oxb.com
The Quality Assurance and the Quality Control teams make up the Quality group at Oxford Biomedica. We make sure that medicinal products are the right quality for their planned use.See details»
Oxford Biomedica Appoints Dr Frank Mathias as Chief
Nov 22, 2022 Oxford Biomedica (LSE:OXB) is an innovative leading viral vector specialist focused on delivering life changing therapies to patients. Oxford Biomedica plc and its …See details»
OXB Selects Jefferies as Joint Corporate Broker and Adviser
Feb 5, 2025 About OXB and Its Mission. With a steadfast commitment to quality and innovation, OXB is dedicated to facilitating life-changing therapies for patients worldwide. The organization …See details»
Oxford Biomedica (France) SAS - OXB
Address. 4 Rue Laurent Fries Illkirch-Graffenstaden Strasbourg, France 67400 Registration No. 813 526 928 - StrasbourgSee details»
Oxford BioMedica Plc Locations - Headquarters & Offices
Save hours of research time with a comprehensive Sales Intelligence Solution. Understand how Oxford BioMedica Plc fits into your total addressable market and Ideal Customer Profile.See details»
Oxford Biomedica plc (OXOA.F) - Yahoo Finance
Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its LentiVector platform technology is a lentiviral …See details»
OXB to present at the Leerink Partners Global Healthcare Conferen
Feb 26, 2025 OXB (LSE: OXB) is a global quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its …See details»
Webcasts, Podcasts and Audio - OXB
Oxford Biomedica PLC, Windrush Court, Transport Way, Oxford, OX4 6LT, United KingdomSee details»
OX-B's
OX-B's is a restaurant chain in Ohio offering wings, wraps, salads, and signature items with online ordering and catering services.See details»
INTRODUCING TH GENERATION LENTIVIRAL VECTORS - oxb.com
VP, Head of Process Development at OXB Supplier of lentiviral vectors for the first FDA approved CAR- T product. FDA approved 1st Over 8,000 patients have been treated with OXB …See details»
Start with Stable. Stepping onto TetraVecta™ Packaging Cells to …
Contact –Oxford Biomedica •partnering@oxb.com Presented at ASGCT, May 2024, Baltimore US Why not start here ? Summary The advantages of stable LV producer cell lines (such as …See details»